NASDAQ: GH

Guardant Health (GH) Stock Analysis & Forecast

Nov 13 close

$151.70−3.16 (−2.0%)

Gekko Brief

Nov 9 close

Guardant Health closed at $158.79 on 9 November 2026, +5.2% on the day. The price sits between the 50-day ($169.26) and 200-day ($131.95) moving averages, inside a 52-week range of $74.55 to $191.05. The GekkoIndex reads 66.3, in the Accumulation zone, up 9.5 points over five sessions. Gekko Fair Value is $182.49, so the price is 13% below it.

The next earnings report is due on 18 February 2027, 95 days away (after close). Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 11.7% across the report. Smart-money activity over the last 90 days includes 1 Congress purchase and 0 sales. Over the last 30 days there were 2 unusual options signals. Seasonally, the next 20 trading days from this point averaged +8.8% over the last 5 years, rising in 3 of them.

19 firms rate the stock: 19 buy, 0 hold and 0 sell, with a consensus target of $202.24. A typical daily move is about 6.7%, and a typical 20-day move about 11.1%. On the swing-trade checklist, 4 items read supportive and 0 read as a headwind.

A plain summary of the figures as of the Nov 9, 2026 close.

Guardant Health price vs fair value

$181.49$151.70Nov ’25May ’26Nov ’26
Close $151.70200-day averageGekko Fair Value $181.49

Guardant Health quick facts

Market cap
$20.54B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$3.68
Revenue, TTM
$1.28B
Profit margin
-37.9%
Dividend yield
—
Beta
1.66
Volume
1.29M avg 2.26M
1-year return
+55.0%
Typical daily move
±6.9%
Typical 20-day move
±11.1%
50-day average
$168.65
200-day average
$132.79
Next earnings
Feb 18 after close
Shares outstanding
135.3M
52-week range
$74.55$191.05

Guardant Health swing-trade checklist

Guardant Health scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive2 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $151.70 sits between the 50-day ($168.65) and 200-day ($132.79) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    67.1, Accumulation

    Reading 67.1 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    16.4% below

    Price is 16.4% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneymixed

    Mixed

    Last 90 days: Congress 1 buy / 0 sales. Last 30 days: 2 unusual options signals.

    See smart money
  • Earnings risksupportive

    Reports in 95 days

    Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +3.2% on average

    From this point in the calendar, the next 20 trading days averaged +3.2% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Guardant Health stock chart and price history

Guardant Health closed at $151.70 on Nov 13, 2026, +55.0% over the past year, inside a 52-week range of $74.55 to $191.05.

Close50-day average200-day averageVolume
Guardant Health share price, past year, with 50-day and 200-day moving averages and volume$50$100DecJan 2026FebMarAprMayJunJulAugSepOctNov151.70

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−8.5%
3 months
−6.2%
6 months
+59.8%
1 year
+55.0%
The full GH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GH in Gekko

Follow Guardant Health through every session

Put GH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track GH in GekkoFree for 7 days. No credit card required.

About Guardant Health

Guardant Health focuses on precision oncology, offering blood-based diagnostic tests along with data sets and analytical tools for patients dealing with cancer, both in the United States and abroad. Its work centers on liquid biopsy testing, with products such as Guardant360 and GuardantOMNI aimed at people with advanced-stage disease, and the Guardant Reveal Test supporting treatment decisions for those in earlier stages. The company also markets Guardant360 for tissue genotyping and a coronavirus detection test called Guardant-19.

Beyond its diagnostic products, Guardant Health runs GuardantINFORM, a research platform built on genomic data gathered from liquid biopsies of advanced cancer patients, and is developing tools including LUNAR-2 for early colorectal cancer detection and GuardantConnect, a platform meant to connect patients with relevant clinical trials. The company also works with biopharmaceutical firms and medical institutions, providing services such as companion diagnostic development, regulatory support, clinical study management, and kit fulfillment.

Guardant Health was founded in 2011 and is based in Redwood City, California. Its shares are listed on the NASDAQ under the ticker GH.

Listed
NASDAQ
Sector
Health services
Industry
Medical/Nursing services
Website
guardanthealth.com

Guardant Health GekkoIndex: the smart money zone

Guardant Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.1, in the Accumulation zone, down 2.3 points over five sessions.

010067.1Accumulation

Down 2.3 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying21+4.7%+6.2%+0.7%+10.5%
Accumulation (current zone)210+1.1%+2.7%+9.9%+28.3%
Neutral400+2.1%+4.1%+7.5%+19.2%
Distribution60+2.1%+4.5%+5.2%+17.6%
Selling10−2.9%+0.1%+8.1%+15.4%

Average GH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the GH price, zone by zone.Track GH in Gekko

Is Guardant Health stock overvalued? Gekko Fair Value

Guardant Health trades 16.4% below Gekko Fair Value of $181.49, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Guardant Health shares are worth, recalculated every trading day.

$181.49

Gekko Fair Value, Nov 14, 2026

16.4% Undervalued

At the end of Aug 2026 the price was 12.3% below the estimate.

Gekko Fair ValueShare price, month end
$181$152Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open GH in Gekko

Guardant Health insider and Congress trading

No open-market insider purchases were filed for Guardant Health, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for GH in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every GH insider filing, plotted on the chart in Gekko.Open GH in Gekko

Congress trades last 90 days

1trade disclosed: 1 purchase and 0 sales.

MemberTypeAmountDisclosed
Jonathan Jackson
House, IL, purchase
Purchase$15,001 - $50,000Oct 20
traded Sep 28

From congressional disclosures, which report amounts as ranges.

Buybacks

Guardant Health has been buying back its own shares.

Bought back, quarter ended Mar 31, 2025
$45.01M
As a share of market cap
0.22%

From company filings.

Unusual options activity last 30 days

2signals, 0% of the flagged premium in calls.

Latest: Bearish flow on Nov 3, $1.07M in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds GH.

0added0opened1trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Guardant Health earnings: next date and track record

Guardant Health reports on Feb 18, 2027, after the close (95 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±11.7%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+21.6%Nov ’24−12.5%Feb ’25−1.3%Apr ’25−5.4%Jul ’25+32.8%Oct ’25−4.0%Feb ’26+3.7%May ’26+12.4%Jul ’26

Last earnings call, Jul 30, 2026 AI summary

What they said
Guardant Health reported Q2 2026 revenue of $335 million, up 44% year-over-year, with broad-based growth across Oncology, Biopharma & Data, and Screening. Oncology revenue grew 38% to $219 million with test volumes surging 63% to ~104,000 tests. Key milestones include FDA approval for Guardant360 Liquid CDx, a higher-throughput Shield workflow, ACS guideline inclusion, and UnitedHealth Group coverage for Shield. Reveal MRD product volume exceeded 100% growth year-over-year.
Guidance
No explicit forward-looking financial guidance was provided in this excerpt. Management highlighted ~$400 billion in addressable market potential across therapy selection, recurrence monitoring, cancer screening, and multi-disease screening as long-term growth drivers.
ReportedEPSSurpriseRevenueSurpriseMove
Jul 30, 2026−$0.89
est −$0.74
−20.3%$335.0M
est $314.2M
+6.6%+12.4%
May 7, 2026−$0.45
est −$0.47
+5.0%$301.7M
est $279.2M
+8.1%+3.7%
Feb 19, 2026−$0.50
est −$0.77
+35.5%$281.3M
est $272.4M
+3.2%−4.0%
Oct 29, 2025−$0.39
est −$0.48
+18.7%$265.2M
est $267.6M
−0.9%+32.8%
Jul 30, 2025−$0.44
est −$0.72
+38.9%$232.1M
est $235.7M
−1.5%−5.4%
Apr 30, 2025−$0.49
est −$0.85
+42.4%$203.5M
est $211.4M
−3.8%−1.3%
Feb 20, 2025−$0.62
est −$0.50
−23.1%$201.8M
est $192.5M
+4.8%−12.5%
Nov 6, 2024−$0.88
est −$0.74
−18.9%$191.5M
est $189.0M
+1.3%+21.6%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Guardant Health stock forecast and analyst price targets

Analysts’ average 12-month price target for Guardant Health is $200.76, +32.3% from the last close, from 19 firms rating the stock in the last 90 days.

$200.76consensus 12-month target, +32.3% from the last close
Low $180High $225
Buy19
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 19 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 10Piper SandlerBuy, reiterated$190+25.2%
Nov 6Stifel NicolausBuy, maintained$180+18.7%
Nov 6Robert W. BairdBuy, maintained$196+29.2%
Nov 6RBC CapitalBuy, maintained$200+31.8%
Nov 6Goldman SachsBuy, maintained$210+38.4%
+9.9%average 20-day move after past Accumulation readings
+3.2%average move over the next 20 trading days in the last 5 years
±6.9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Guardant Health seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Guardant Health averaged +3.2% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−11.8%2021−7.2%2022+15.8%2023+15.1%2024+8.8%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−0.6%1 of 5
Next 10 trading days+5.8%5 of 5
Next 15 trading days+5.5%4 of 5
Next 20 trading days+3.2%3 of 5
Next 30 trading days−7.5%2 of 5

For scale, GH’s typical 20-trading-day move in either direction is about 11.1%.

Guardant Health market cap and key statistics

Guardant Health’s market cap is $20.54B and revenue of $1.28B over the last twelve months.

Valuation

Market cap
$20.54B
EPS, TTM
−$3.68
Gekko Fair Value
$181.49

Trading

Volume
1.29M
Avg volume, 20 days
2.26M
52-week high
$191.05
52-week low
$74.55
Shares outstanding
135.3M

Financials

Revenue, TTM
$1.28B
Profit margin
-37.9%
Return on equity
-4584%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
1.66
Typical daily move
±6.9%
Typical 20-day move
±11.1%

Guardant Health peers

Guardant Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LHLabcorp−1.0%Neutral8.5% above
SOLVSolventum0.0%Neutral17.0% below
BTSGBrightSpring Health Services0.0%Neutral11.0% above
EHCEncompass Health−0.4%Neutral14.7% above
ENSGEnsign+0.3%Neutral15.6% above
DVADaVita−0.3%Accumulation25.6% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical/Nursing services

Guardant Health stock FAQ

What is Guardant Health’s market cap?

Guardant Health’s market cap is $20.54B at the Nov 13, 2026 close of $151.70, with 135.3M shares outstanding.

What is the Guardant Health stock forecast?

The consensus analyst 12-month price target for Guardant Health is $200.76, +32.3% from the last close. Of the 19 firms that rated the stock in the last 90 days, 19 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Guardant Health stock overvalued or undervalued?

On Gekko’s estimate Guardant Health is undervalued: the Nov 13, 2026 close of $151.70 is 16.4% below Gekko Fair Value of $181.49. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Guardant Health report earnings next?

Guardant Health is expected to report on Feb 18, 2027, after the market closes (95 days away). Analysts expect earnings of −$0.74 per share on revenue of $370.3M. Guardant Health beat the earnings estimate in 5 of its last 8 reports, moving 11.7% on average across the report.

What is Guardant Health’s 52-week high and low?

Guardant Health’s 52-week high is $191.05 and its 52-week low is $74.55; it closed at $151.70 on Nov 13, 2026, +55.0% over the past year.

Is Guardant Health stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 2 as mixed (trend and smart money). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Guardant Health?

Gekko flagged 2 unusual options signals in Guardant Health over the last 30 days, with $0 of flagged premium in calls and $4.70M in puts. The latest, bearish flow, was on Nov 3, 2026 with $1.07M in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Guardant Health the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.